Monday, 10 August 2020


Celgene invests $100 mn in Acetylon

30 July 2013 | News | By BioSpectrum Bureau

Acetylon intends to use the money for the research and testing of ACY-1215, a potential myeloma-fighting cancer drug, as well as three other cancer treatments

Acetylon intends to use the money for the research and testing of ACY-1215, a potential myeloma-fighting cancer drug, as well as three other cancer treatments

Singapore: Biotech giant Celgene has invested $100 million in Acetylon Pharmaceuticals, a developer of small- molecule cancer drugs. The Boston Globe has reported that this investment could lead to a $1.6 billion buyout in the future.

Acetylon intends to use the money for the research and testing of ACY-1215, a potential myeloma-fighting cancer drug, as well as three other cancer treatments. Celgene has been increasing its New England presence over the past two years. This new investment adds to Celgene's $15 million equity stake in Acetylon, which it took back in 2012.


Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account




Podcast

 

Survey Box

Should we be cautious of viewing COVID-19 vaccine as silver bullet?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls